Featured Publications
Platelet-derived TLT-1 promotes tumor progression by suppressing CD8+ T cells
Tyagi T, Jain K, Yarovinsky TO, Chiorazzi M, Du J, Castro C, Griffin J, Korde A, Martin KA, Takyar SS, Flavell RA, Patel AA, Hwa J. Platelet-derived TLT-1 promotes tumor progression by suppressing CD8+ T cells. Journal Of Experimental Medicine 2022, 220: e20212218. PMID: 36305874, PMCID: PMC9814191, DOI: 10.1084/jem.20212218.Peer-Reviewed Original ResearchConceptsCD8 T cellsT cellsTLT-1Non-small cell lung cancer patientsCell lung cancer patientsTREM-like transcript-1Tumor immunosuppressive mechanismsT cell suppressionLung cancer patientsPatient T cellsNF-κB pathwayPatient-derived tumorsDistinct activation phenotypesNSCLC patientsImmunosuppressive mechanismsSyngeneic tumorsHumanized miceImmunoregulatory rolePrognostic significanceImmunocompetent miceCancer patientsCell suppressionActivation phenotypeReduced tumorTumor growth
2022
High-multiplexing quantitative CodePlex proteomic profiling of platelets in triple-negative breast cancer (TNBC) patients and healthy subjects.
Han E, Gu S, Steinle M, Gu V, Tyagi T, Mackay S, Hwa J, Zhou J. High-multiplexing quantitative CodePlex proteomic profiling of platelets in triple-negative breast cancer (TNBC) patients and healthy subjects. Journal Of Clinical Oncology 2022, 40: e15017-e15017. DOI: 10.1200/jco.2022.40.16_suppl.e15017.Peer-Reviewed Original ResearchTriple-negative breast cancerTriple-negative breast cancer patientsBreast cancer patientsCancer patientsHealthy controlsIL-8IL-9TNBC patientsPilot studyNegative breast cancer patientsAberrant platelet activationPlatelet releasateDifferential cytokine profilesPlatelet lysateNegative breast cancerSmall pilot studySerum/plasmaImmune panelMinimal IFNIL-17AMIP-1aCytokine profileIL-10IL-15Healthy patients